OASMY (Vivesto AB) EPS (Diluted): $-0.01 (TTM As of Mar. 2026)


OASMY Vivesto AB OASMY
26 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Vivesto AB EPS (Diluted)?

Vivesto AB OASMY 26 EPS (Diluted) is $-0.01 as of Mar. 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Vivesto AB's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01.

Vivesto AB's EPS (Basic) for the three months ended in Mar. 2026 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01.

Vivesto AB's EPS without NRI for the three months ended in Mar. 2026 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was 58.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Vivesto AB's highest 3-Year average EPS without NRI Growth Rate was 68.70% per year. The lowest was -112.30% per year. And the median was 3.00% per year.


Vivesto AB  (OTCPK:OASMY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vivesto AB EPS (Diluted) Related Terms


Vivesto AB EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Vivesto AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB EPS (Diluted) Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.18 -0.06 -0.02 -0.02

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.01 0.00

OASMY vs ZTS, UTHR, VTRS: EPS (Diluted) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vivesto AB's PE Ratio falls into.


OASMY
26GF Score
Vivesto AB OASMY
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Vivesto AB's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as

Diluted EPS (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.667-0)/206.059
=-0.02

Vivesto AB's Diluted EPS for the quarter that ended in Mar. 2026 is calculated as

Diluted EPS (Q: Mar. 2026 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.74-0)/369.046
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of $-0.01 mean?
Vivesto AB (OASMY) has a EPS (Diluted) of $-0.01 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Vivesto AB and its competitors.
Is Vivesto AB's EPS (Diluted) too high?
Vivesto AB's current EPS (Diluted) is $-0.01. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's EPS (Diluted) compare to ZTS and UTHR?
Vivesto AB's EPS (Diluted) of $-0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Vivesto AB and its competitors. Vivesto AB's current EPS (Diluted) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current EPS (Diluted) of $-0.01. The current EPS (Diluted) is $-0.01. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Vivesto AB (OASMY), the current EPS (Diluted) is $-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges VIVE:SwedenOMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OASMY

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price